UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2026
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
99.1
|
30 July
2026 - “2026 Half Year
Results”
|
|
|
|
99.1
Haleon plc: 2026 Half Year Results
30 July 2026: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces its
half year results statement for the year ending 31 December 2026 is
available at http://www.rns-pdf.londonstockexchange.com/rns/4443O_1-2026-7-29.pdf.
The half year results statement will also be available on the
Haleon website www.haleon.com/investors,
and the results have been submitted in full unedited text to the
Financial Conduct Authority's National Storage Mechanism and will
shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Dividend
Consistent with our policy to pay approximately one third of the
prior year full year dividend as the interim dividend the Board has
declared a H1 2026 interim dividend of 2.4 pence per ordinary
share, up 9% on the interim dividend in 2025. This interim dividend
is expected to be paid on 17 September 2026 to holders of ordinary
shares and US American Depositary Shares (ADS) on the register as
of 14 August 2026 (the record date). The ex-dividend date is
expected to be 13 August 2026 for ordinary shareholders and 14
August 2026 for holders of ADS. For ordinary shareholders wishing
to participate in the Dividend Reinvestment Programme (DRIP), the
election deadline for the DRIP is 28 August 2026. The DRIP is
provided by Equiniti Financial www.shareview.co.uk.
Subject to market conditions and Board approval, Haleon expects to
grow its ordinary dividend at least in line with adjusted
earnings.
Presentation for analysts and shareholders
A recorded results presentation by Brian McNamara, Chief Executive
Officer, and Dawn Allen, Chief Financial Officer, will be available
shortly after 7:00am BST (8:00 am CEST) on 30 July 2026 and can be
accessed at www.haleon.com/investors.
This will be followed by a Q&A session at 9:00am BST (10:00am
CEST).
For analysts and shareholders wishing to ask questions, please use
the dial-in details below which will have a Q&A
facility:
|
UK:
|
+44 (0) 808 189 0158
|
|
US:
|
+1 855 979 6654
|
|
All other:
|
+44 (0) 203 936 2999
|
|
Passcode:
|
081063
|
An archived webcast of the Q&A call will be available later on
the day of the results and can be accessed at www.haleon.com/investors.
This information contains regulated information as per 6.3.7R of
the Disclosure and Transparency Rules of the Financial Conduct
Authority.
Amanda Mellor
Company Secretary
Enquiries
|
Investors
|
Media
|
|
Jo
Russell
|
+44
7787 392441
|
Zoë
Bird
|
+44
7736 746167
|
|
Rakesh
Patel
|
+44
7552 484646
|
Victoria
Durman
|
+44 7894 505730
|
|
Email: investor-relations@haleon.com
|
Email:
corporate.media@haleon.com
|
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused
on better everyday health. Our people, our brands, our research,
our investment and our innovation are aimed at improving the
everyday health of consumers. Our product portfolio spans six major
categories - Oral Health, Vitamins, Minerals and Supplements (VMS),
Pain Relief, Respiratory Health, Digestive Health and Therapeutic
Skin Health and Other. Our superior brands - such as
Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers
and are recommended by health professionals around the
world.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
Date:
July 30, 2026
|
By:
|
/s/
Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|

